Cynosure, Inc. (Nasdaq: CYNO) today announced the presentation of a new study that demonstrates the clinical benefits of using a 1440 nm wavelength in laser-assisted lipolysis to disrupt fat tissue and tighten skin through tissue coagulation. The study, led by Barry DiBernardo, M.D., Medical Director of New Jersey Plastic Surgery, is one of six Cynosure-related abstracts being presented this week at the 2010 American Society for Laser Medicine and Surgery (ASLMS) Annual Conference in Arizona.
Dr. DiBernardo's study evaluated the fat-disruption and tissue tightening that occurred in abdominal tissue treated with three separate wavelengths, including a 1440 nm laser. The 1440 nm wavelength is the heart of Cynosure's Smartlipo Triplex, which was introduced in late 2009 as the newest member of Cynosure's family of workstations for laser-assisted lipolysis. The Smartlipo Triplex is the highest-power laser energy device approved for fat removal by the U.S. Food and Drug Administration.
"At the same power and doses, tissue treated with the 1440 nm laser disrupted a larger area of fat tissue and demonstrated greater tissue tightening effects than the other wavelengths," Dr. DiBernardo said. "The conclusion that can be drawn from this research is that, in terms of the efficiency of fat removal and collagen remodeling, wavelength and laser energy play an integral role in patient outcomes. In comparing these three unique wavelengths, the results from the 1440 nm laser demonstrated the most pronounced histological effects."
Michael Davin, president and chief executive officer of Cynosure, said, "The research presented at ASLMS further validates the investment we have made to increase the efficiency and performance of our Smartlipo technology with the addition of a 1440 nm wavelength. The higher-powered laser, combined with enhancements such as SmartSense with ThermaGuide, which monitors and controls the flow of energy during laser-assisted lipolysis, gives our technology a strong competitive advantage in the marketplace. Moreover, the study highlights a tenet of our corporate strategy – to support our brands with comprehensive scientific research."
Highlights from other Smartlipo-related abstracts being presented at ASLMS this week, include: